Colleen Moretti, Assistant Editor for CURE®, joined MJH Life Sciences in November 2020. Colleen is a graduate of Monmouth University, where she studied communication with a focus in journalism and public relations. In her free time, she enjoys learning to cook new meals, spending time with her adopted beagle, Molly, or sitting on the beach with a good book. Email her at cmoretti@curetoday.com
Educated Patient® Multiple Myeloma Summit MGUS/Smoldering Myeloma Presentation: March 12, 2022
March 30th 2022Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.
Read More
Swapping Surgery for Adjuvant Therapy May Improve Outcomes in Patients With Stage 3 Melanoma
March 23rd 2022Patients with stage 3 melanoma, a type of skin cancer, that has metastasized to the lymph nodes may benefit from skipping lymph node removal surgery and receiving treatment with adjuvant therapy, although more research is needed in this area.
Read More
Tafinlar Plus Mekinist May Safely Improve Long-Term Survival in Patients with Rare Thyroid Cancer
February 4th 2022After four years of additional follow-up, survival continued to improve and side effects remained tolerable in patients with anaplastic thyroid cancer receiving Tafinlar plus Mekinist.
Read More
Healthy Diet and Lifestyle May Improve Survival Rates for Patients With Stage 3 Colon Cancer
January 31st 2022Patients with stage 3 colon cancer should feel empowered to start a healthy lifestyle and diet, says a researcher, after recent study results demonstrated positive survival and recurrence outcomes.
Read More
Kymriah Shows ‘Huge Potential’ for Patients With Heavily Pretreated, Relapsed Follicular Lymphoma
January 24th 2022Kymriah may represent a more effective option than currently available treatments for patients with heavily pretreated follicular lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Read More
Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL
December 14th 2021The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.
Read More